This translational, clinically oriented book describes in detail novel approaches to cancer immunotherapy, current strategies to target tumor immunosuppression, and prognostic biomarkers for personalized cancer treatments. Since the first, very successful edition of the book was published in 2015, the original chapters have been significantly updated and entirely new chapters are included on, for example, cancer immunoprevention, aptamer-mediated cancer gene therapy, haploidentical bone marrow transplantation for pediatric malignancies, and nanoimmunotherapy.

Nima Rezaei gained his medical degree from Tehran University of Medical Sciences in 2002 and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also undertook a short-term fellowship of Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Since 2010, Dr. Rezaei has worked at the Department of Immunology, School of Medicine, Tehran University of Medical Sciences. He is now the Vice Dean of International Affairs, School of Medicine, Tehran University of Medical Sciences; Director of the Global Academic Program, Tehran University of Medical Sciences; and co-founder and Deputy President of the Research Center for Immunodeficiencies. He is also the Founding President of Universal Scientific Education and Research Network (USERN). Dr. Rezaei has already been the director of more than 50 research projects and has designed and participated in several international collaborative projects. He is an editorial assistant or board member for more than 30 international journals. He has edited more than 20 books, has presented more than 450 lectures/posters in congresses/meetings, and has published more than 750 articles in international scientific journals